The TLR9 agonist PF-3512676 (Formerly CPG 7909) induces T cell-mediated tumor regression synergistically with paclitaxel or treg depletion in a metastatic murine cancer model

被引：0
|
作者：
Weeratna, Risini D.
Vicari, Alain P.
Bourne, Liana
Davis, Heather L.
Krieg, Arthur
机构：
[1] Coley Pharmaceut Grp, Wellesley, MA USA
[2] Coley Pharmaceut Grp, Ottawa, ON, Canada
来源：
JOURNAL OF IMMUNOTHERAPY | 2006年 / 29卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：678 / 679
页数：2
相关论文
共 8 条
  • [1] Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse
    Vicari, Alain P.
    Luu, Rachel
    Zhang, Ningli
    Patel, Shobhna
    Makinen, Shawn R.
    Hanson, Douglas C.
    Weeratna, Risini D.
    Krieg, Arthur M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (04) : 615 - 628
  • [2] Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse
    Alain P. Vicari
    Rachel Luu
    Ningli Zhang
    Shobhna Patel
    Shawn R. Makinen
    Douglas C. Hanson
    Risini D. Weeratna
    Arthur M. Krieg
    Cancer Immunology, Immunotherapy, 2009, 58 : 615 - 628
  • [3] Toll-like-receptor 9 (TLR-9) agonist PF-3512676 (CPG 7909) in combination with chemotherapy in the treatment of non-small cell lung cancer (NSCLC)
    Gauler, T.
    Schuett, P.
    Eberhardt, W.
    ANNALS OF ONCOLOGY, 2007, 18 : 24 - 25
  • [4] Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer
    Yamada, Kazuhiko
    Nakao, Masao
    Fukuyama, Chikara
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sekine, Ikuo
    Kunitoh, Hideo
    Ohe, Yuichiro
    Ohki, Emiko
    Hashimoto, Junichi
    Tamura, Tomohide
    CANCER SCIENCE, 2010, 101 (01) : 188 - 195
  • [5] Enhancement of anti-tumor efficacy of paclitaxel by CpG ODN; TLR9 agonist in metastatic murine cancer models
    Weeratna, R
    Bourne, L
    Sullivan, S
    Davis, H
    Krieg, A
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : S56 - S57
  • [6] RANDOMIZED PHASE II TRIAL OF ERLOTINIB WITH OR WITHOUT PF-3512676 (CPG 7909, A TOLL-LIKE RECEPTOR 9 [TLR9] AGONIST) IN PATIENTS WITH ADVANCED RECURRENT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Belani, Chandra P.
    Nemunaitis, John J.
    Chachoua, Abraham
    Eisenberg, Peter D.
    Raez, Luis E.
    Cuevas, Juan D.
    Mather, Cecile B.
    Benner, Rebecca J.
    Meech, Sandra J.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1218 - S1219
  • [7] Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity
    Masuda, Yuki
    Nawa, Daiki
    Nakayama, Yoshiaki
    Konishi, Morichika
    Nanba, Hiroaki
    JOURNAL OF LEUKOCYTE BIOLOGY, 2015, 98 (06) : 1015 - 1025
  • [8] Modulation of T cell and macrophage tumor infiltration by the TLR9 agonist lefitolimod in a murine model of colorectal cancer.
    Schmidt, Manuel
    Oswald, Detlef
    Volz, Barbara
    Wittig, Burghardt
    Kapp, Kerstin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
1